登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000516 证券简称：国际医学 公告编号：2025-054 西安国际医学投资股份有限公司关于2025年度 向特定对象发行股票不存在直接或通过利益 相关方向发行对象提供财务资助或补偿的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 西安国际医学投资股份有限公司（以下简称"公司"）于2025年12月3日召开第十三届董事会第九次会 议，审议通过了关于公司2025年度向特定对象发行股票的相关议案。现就公司本次向特定对象发行股票 中公司不存在直接或通过利益相关方向参与认购的投资者提供财务资助或补偿事宜，公司承诺如下： 西安国际医学投资股份有限公司董事会 二○二五年十二月四日 证券代码：000516 证券简称：国际医学 公告编号：2025-053 西安国际医学投资股份有限公司关于2025年度向特定对象发行股票摊薄即期回报的风险提示及填补回报 措施和相关主体承诺的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 本公告中关于西安国际医学投 ...

Core Insights - The company aims to develop a differentiated strategy to build competitive advantages and enhance service value [2] Business Strategy - The company plans to adjust its business structure by actively laying out in various sectors including medical aesthetics, rehabilitation, women's and children's health, health management, traditional Chinese medicine, assisted reproduction, mental health, and special services [2] - The company intends to expand its services by opening elderly care facilities and specialized departments such as proton therapy to meet market demand [2] Operational Efficiency - The company will focus on resource integration and departmental optimization, strengthening cost control and management of pharmaceutical supplies, while optimizing financial costs [2]

Group 1: 2024 Overall Business Performance - The company achieved a total outpatient and emergency service volume of 2.5727 million, a year-on-year increase of 7.70% [1] - The inpatient service volume reached 205,700, reflecting a year-on-year growth of 10.73% [1] - The total operating revenue for the year was 4.815 billion, with a year-on-year increase of 4.28% [2] - The net profit attributable to the parent company was -254 million, a reduction in loss by 31.01% [2] Group 2: Q1 2025 Business Performance - In Q1 2025, the company reported an operating revenue of 999.7 million, a decrease of 14.99% compared to the same period last year [3] - The net profit attributable to the parent company was -106 million, a decline of 1.37% year-on-year [3] - The net operating cash flow was 244 million, indicating stable cash flow management [3] Group 3: 2024 Operational Highlights - Xi'an High-tech Hospital generated operating revenue of 1.525 billion, a year-on-year increase of 2.68% [3] - Xi'an International Medical Center Hospital achieved operating revenue of 3.274 billion, with a year-on-year growth of 7.60% [3] - The outpatient and emergency service volume at the International Medical Center Hospital reached 1.4182 million, a year-on-year increase of 18.88% [4] - The inpatient service volume was 139,700, reflecting a year-on-year growth of 15.32% [4] Group 4: Proton Center Project and Digitalization - The proton therapy center project is progressing, with the core component, the cyclotron, installed by June 18, 2024, and expected to be operational by the end of 2025 [5][6] - The company has completed local deployment of medical intelligent models, integrating with core business systems to enhance operational efficiency [7] Group 5: Quality Improvement and Service Expansion - The hospital is advancing its three-tier evaluation work, focusing on system optimization and quality enhancement [8] - The company is expanding into high-end medical services, including aesthetic medicine, rehabilitation, and proton therapy, to meet diverse health needs [9] - The company is adapting to ongoing healthcare policy reforms by refining operations and adjusting business structures to maintain service quality [10]